Mann Eye Institute has taken a significant step forward in retinal care with the introduction of the FDA-authorized LumiThera Valeda® Light Delivery System, a pioneering treatment for patients with dry age-related macular degeneration (AMD). As the first practice in Houston to offer this non-invasive therapy, Mann Eye Institute is expanding access to one of the few clinically validated options for a condition that affects millions of older adults and is the leading cause of vision loss in people over 65. This move underscores the institute’s long-standing commitment to bringing breakthrough innovations to its patients.

The Valeda system uses photobiomodulation—precisely calibrated light therapy targeting retinal cells—to rejuvenate and restore visual function. It delivers specific wavelengths of light that stimulate cellular energy production and reduce inflammation, with the goal of slowing disease progression and potentially improving visual acuity. Clinical studies have shown promising outcomes, including a measurable gain in visual performance over a two-year period. The treatment is fast, painless, and designed for outpatient use, making it highly convenient for patients and easy to integrate into standard care pathways.

By adopting this groundbreaking technology, Mann Eye Institute reinforces its mission to “See Life Better” by offering patients access to the most advanced care available. With dry AMD previously having limited treatment options, this therapy offers new hope and a proactive approach to managing a chronic degenerative disease. The introduction of Valeda not only enhances Mann Eye Institute’s comprehensive vision services but also signals a broader shift in the field—toward early intervention and functional preservation for aging eyes.